Epigenomics AG (Epigenomics AG) Total Assets : $4.57 Mil (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG Total Assets?

Epigenomics AG's Total Assets for the quarter that ended in Jun. 2023 was $4.57 Mil.

During the past 12 months, Epigenomics AG's average Total Assets Growth Rate was -75.40% per year. During the past 3 years, the average Total Assets Growth Rate was 25.30% per year. During the past 5 years, the average Total Assets Growth Rate was -10.10% per year. During the past 10 years, the average Total Assets Growth Rate was -3.00% per year.

During the past 13 years, Epigenomics AG's highest 3-Year average Total Assets Growth Rate was 25.30%. The lowest was -30.30%. And the median was -15.20%.

Total Assets is connected with ROA %. Epigenomics AG's annualized ROA % for the quarter that ended in Jun. 2023 was -138.91%. Total Assets is also linked to Revenue through Asset Turnover. Epigenomics AG's Asset Turnover for the quarter that ended in Jun. 2023 was 0.01.

Epigenomics AG Total Assets Historical Data

The historical data trend for Epigenomics AG's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Total Assets Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Assets

Get a 7-Day Free Trial

24.83

15.54

8.27

27.87

16.79

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Assets	Get a 7-Day Free Trial															21.80	18.78	16.79	11.86	4.57

Epigenomics AG Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Epigenomics AG's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as

Total Assets	=	Total Equity (A: Dec. 2022 )	+	Total Liabilities (A: Dec. 2022 )
	=	10.775	+	6.017
	=	16.79

Epigenomics AG's Total Assets for the quarter that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (Q: Jun. 2023 )	+	Total Liabilities (Q: Jun. 2023 )
	=	2.068	+	2.501
	=	4.57

Epigenomics AG (OTCPK:EPGNF) Total Assets Explanation

Total Assets is connected with ROA %.

Epigenomics AG's annualized ROA % for the quarter that ended in Jun. 2023 is

ROA %	=	Net Income (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-11.412	/	( (11.862	+	4.569)	/ 2 )
	=	-11.412	/	8.2155
	=	-138.91 %

Note: The Net Income data used here is four times the quarterly (Jun. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Epigenomics AG's Asset Turnover for the quarter that ended in Jun. 2023 is

	Asset Turnover
=	Revenue (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
=	0.076	/	( (11.862	+	4.569)	/ 2 )
=	0.076	/	8.2155
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Epigenomics AG Total Assets Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (Epigenomics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ECX:Germany

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines

From GuruFocus

Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET

By ACCESSWIRE ACCESSWIRE • 07-23-2020